Treace Medical Concepts Q2 EPS $(0.20) Beats $(0.24) Estimate, Sales $41.95M Beat $40.85M Estimate
Portfolio Pulse from vinayak@benzinga.com
Treace Medical Concepts (NASDAQ:TMCI) reported Q2 losses of $(0.20) per share, beating the analyst consensus estimate of $(0.24) by 16.67%. The company also reported quarterly sales of $41.95 million, beating the estimate of $40.85 million by 2.70%. This represents a 13.04% increase in losses and a 40.00% increase in sales compared to the same period last year.
August 08, 2023 | 8:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Treace Medical Concepts reported better than expected Q2 results, with both EPS and sales beating estimates. This could potentially lead to a positive market reaction.
Treace Medical Concepts reported better than expected Q2 results, with both EPS and sales beating estimates. This is generally seen as a positive signal by the market and could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100